M. Dreyling, H. C. Kluin-nelemans, S. Beà, W. Klapper, N. Vogt et al., Update on the molecular pathogenesis and clinical www.impactjournals.com/oncotarget treatment of mantle cell lymphoma: report of the 11th annual conference of the European Mantle Cell Lymphoma Network, Leuk Lymphoma, vol.54, pp.699-707, 2013.

H. C. Kluin-nelemans, E. Hoster, O. Hermine, J. Walewski, M. Trneny et al., Treatment of older patients with mantle-cell lymphoma, N Engl J Med, vol.367, pp.520-551, 2012.

P. Jares, D. Colomer, and E. Campo, Molecular pathogenesis of mantle cell lymphoma, J Clin Invest, vol.122, pp.3416-3423, 2012.

S. Bàe, I. Salaverria, L. Armengol, M. Pinyol, V. Fernández et al., Uniparental disomies, homozygous deletions, amplifications, and target genes in mantle cell lymphoma revealed by integrative high-resolution whole-genome profiling, Blood, vol.113, pp.3059-69, 2009.

S. Ek, C. Högerkorp, M. Dictor, M. Ehinger, and C. Borrebaeck, Mantle Cell Lymphomas Express a Distinct Genetic Signature Affecting Lymphocyte Trafficking and Growth Regulation as Compared with Subpopulations of Normal Human B Cells, Cancer Res, vol.62, pp.4398-405, 2002.

W. Hofmann, S. Vos-de, K. Tsukasaki, W. Wachsman, G. S. Pinkus et al., Altered apoptosis pathways in mantle cell lymphoma detected by oligonucleotide microarray, Blood, vol.98, pp.787-794, 2001.

J. Deng, N. Carlson, K. Takeyama, P. Dal-cin, M. Shipp et al., BH3 profiling identifies three distinct classes of apoptotic blocks to predict response to ABT-737 and conventional chemotherapeutic agents, Cancer Cell, vol.12, pp.171-185, 2007.

C. Tse, A. R. Shoemaker, J. Adickes, M. G. Anderson, J. Chen et al., ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor, Cancer Res, vol.68, pp.3421-3428, 2008.

A. W. Roberts, J. F. Seymour, J. R. Brown, W. G. Wierda, T. J. Kipps et al., Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease, J Clin Oncol, vol.30, pp.488-496, 2012.

A. J. Souers, J. D. Leverson, E. R. Boghaert, S. L. Ackler, N. D. Catron et al., ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets, Nat Med, vol.19, pp.202-210, 2013.

M. S. Davids and A. Letai, ABT-199: Taking Dead Aim at BCL-2, Cancer Cell, vol.23, pp.139-141, 2013.

J. A. Burger and R. J. Ford, The microenvironment in mantle cell lymphoma: cellular and molecular pathways and emerging targeted therapies, Semin Cancer Biol, vol.21, pp.308-312, 2011.

A. V. Kurtova, A. T. Tamayo, R. J. Ford, and J. A. Burger, Mantle cell lymphoma cells express high levels of CXCR4, CXCR5, and VLA-4 (CD49d): importance for interactions with the stromal microenvironment and specific targeting, Blood, vol.113, pp.4604-4613, 2009.

J. M. Tromp, C. R. Geest, E. Breij, J. A. Elias, J. Van-laar et al., Tipping the Noxa/Mcl-1 balance overcomes ABT-737 resistance in chronic lymphocytic leukemia, Clin Cancer Res, vol.18, pp.487-498, 2012.

M. Vogler, M. Butterworth, A. Majid, R. J. Walewska, X. Sun et al., Concurrent up-regulation of BCL-XL and BCL2A1 induces approximately 1000-fold resistance to ABT-737 in chronic lymphocytic leukemia, Blood, vol.113, pp.4403-4413, 2009.

M. S. Davids, J. Deng, A. Wiestner, B. J. Lannutti, L. Wang et al., Decreased mitochondrial apoptotic priming underlies stroma-mediated treatment resistance in chronic lymphocytic leukemia, Blood, vol.120, pp.3501-3509, 2012.

L. A. Honigberg, A. M. Smith, M. Sirisawad, E. Verner, D. Loury et al., The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy, Proc Natl Acad Sci U S A, vol.107, pp.13075-13080, 2010.

C. Touzeau, C. Dousset, L. Bodet, P. Gomez-bougie, S. Bonnaud et al., ABT-737 Induces Apoptosis in Mantle Cell Lymphoma Cells with a Bcl-2 high/Mcl-1low Profile and Synergizes with Other Antineoplastic Agents, Clin Cancer Res, vol.17, pp.5973-5981, 2011.

H. J. Coope, P. G. Atkinson, B. Huhse, M. Belich, J. Janzen et al., CD40 regulates the processing of NF-kappaB2 p100 to p52, EMBO J, vol.21, pp.5375-5385, 2002.

H. H. Lee, H. Dadgostar, Q. Cheng, J. Shu, and G. Cheng, NF-kappaB-mediated up-regulation of Bcl-x and Bfl-1/A1 is required for CD40 survival signaling in B lymphocytes, Proc Natl Acad Sci, vol.96, pp.9136-9141, 1999.

M. L. Wang, S. Rule, P. Martin, A. Goy, R. Auer et al., Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma, N Engl J Med, vol.369, pp.507-516, 2013.

B. Y. Chang, M. Francesco, D. Rooij, M. Magadala, P. Steggerda et al., Egress of CD19(+)CD5(+) cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patients, Blood, vol.122, pp.2412-2424, 2013.

T. K. Ko, C. T. Chuah, J. W. Huang, K. P. Ng, and S. T. Ong, The BCL2 inhibitor ABT-199 significantly enhances imatinib-induced www.impactjournals.com/oncotarget cell death in chronic myeloid leukemia progenitors, Oncotarget, vol.5, pp.9033-9038, 2014.

S. Peirs, F. Matthijssens, S. Goossens, I. Van-de-walle, K. Ruggero et al., ABT-199 mediated inhibition of BCL-2 as a novel therapeutic strategy in T-cell acute lymphoblastic leukemia, Blood, 2014.

V. Fresquet, M. Rieger, C. Carolis, M. J. García-barchino, and J. A. Martinez-climent, Acquired mutations in BCL2 family proteins conferring resistance to the BH3 mimetic ABT-199 in lymphoma, Blood, vol.123, pp.4111-4120, 2014.

D. Hallaert, A. Jaspers, C. J. Van-noesel, M. Van-oers, and A. P. Kater, Eldering E. c-Abl kinase inhibitors overcome CD40-mediated drug resistance in CLL: implications for therapeutic targeting of chemoresistant niches, Blood, vol.112, pp.5141-5149, 2008.

N. Saba and A. Wiestner, Do mantle cell lymphomas have an "Achilles heel, Curr Opin Hematol, vol.21, pp.350-357, 2014.

D. Chiron, D. Liberto, M. Martin, P. Huang, X. Sharman et al., Cell-cycle reprogramming for PI3K inhibition overrides a relapse-specific C81S BTK mutation revealed by longitudinal functional genomics in mantle cell lymphoma, Cancer Discov, vol.4, pp.1022-1035, 2014.

X. Zhao, J. Bodo, D. Sun, L. Durkin, J. Lin et al., Combination of ibrutinib with ABT-199: synergistic effects on proliferation inhibition and apoptosis in mantle cell lymphoma cells through perturbation of BTK, AKT, and BCL2 pathways, Br J Haematol, 2014.

S. Maïga, P. Gomez-bougie, S. Bonnaud, C. Gratas, P. Moreau et al., Paradoxical effect of lenalidomide on cytokine/growth factor profiles in multiple myeloma, Br J Cancer, vol.108, pp.1801-1806, 2013.